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mplications for Clinical and Subclinical Atherosclerosis
nes Montero, BS,*§ Josune Orbe, PHD,*† Nerea Varo, PHD,†§ Oscar Beloqui, MD, PHD,‡
osé I. Monreal, MD, PHD,§ José A. Rodríguez, PHD,*† Javier Díez, MD, PHD,† Peter Libby, MD,
osé A. Páramo, MD, PHD*†
amplona, Spain; and Boston, Massachusetts
OBJECTIVES We examined the effect of C-reactive protein (CRP) on matrix metalloproteinase (MMP)
and inhibitor expression in endothelial cells and in patients with clinical and subclinical
atherosclerosis.
BACKGROUND In addition to predicting atherosclerotic vascular disease, CRP may directly promote a
proinflammatory/proatherosclerotic phenotype.
METHODS Human umbilical vein endothelial cells (HUVECs) and aortic endothelial cells (HAECs)
were incubated in the presence or absence of CRP (50 g/ml). Microarray analysis, real-time
polymerase chain reaction, immunological and activity assays for MMPs were performed.
Specific inhibitors of mitogen-activated protein kinase pathway were used. The MMP-1 and -10
plasma levels were measured in apparently healthy subjects (n  70). Immunolocalization of
CRP, MMP-1, and MMP-10 was performed in human mammary arteries and carotid
endarterectomy specimens.
RESULTS C-reactive protein augmented MMP-1 and -10 messenger ribonucleic acid expression in
HUVEC (p  0.05) and HAEC (p  0.01). C-reactive protein stimulation also increased
MMP-1 and -10 protein in conditioned culture medium (p  0.001), as well as MMP
activity (p  0.001). Specific inhibition of p38 or MEK abolished the CRP induction of the
MMP-1, whereas MMP-10 induction blockade required the simultaneous inhibition of p38
and Jun N-terminal kinase pathways. Subjects with CRP values 3 mg/l (n  37) had
increased plasma MMP-1 and -10 (p  0.05), the association being significant after
adjustment for confounding variables (p  0.04 and p  0.008, respectively). The MMP-10
levels were elevated in subjects with higher carotid intima-media thickness (p  0.009).
Increased CRP and MMP-10 colocalized in endothelial layer and macrophage-rich areas in
advanced atherosclerotic plaques.
CONCLUSIONS Increased local and systemic CRP-related MMP activation might provide a link between
inflammation and plaque vulnerability. (J Am Coll Cardiol 2006;47:1369–78) © 2006 by
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.10.070the American College of Cardiology Foundation
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eascular inflammation plays a key role in all stages of
therosclerosis, from the initiation and progression of the
therosclerotic lesion to plaque rupture, and eventually to
See page 1379
he occurrence of cardiovascular events (1). Inflammation
eightens production of biomarkers, such as C-reactive
rotein (CRP), which provide information about the risk of
eveloping cardiovascular disease and may furnish new
riteria for treatment (2).
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ccepted October 10, 2005.C-reactive protein powerfully and independently predicts
yocardial infarction, stroke, and vascular death in a variety
f clinical settings (3,4). In addition, recent studies suggest
hat CRP has direct proatherosclerotic effects on cellular
unctions implicated in atherosclerotic lesion formation: it
romotes endothelial cell (EC) activation, uptake of low-
ensity lipoprotein by macrophages, and expression of
ngiotensin II type 1 receptor by vascular smooth muscle
ells (5–9). However, a possible protective role of CRP in
therogenesis has also been suggested (10).
Atherosclerotic plaques that have ruptured characteristi-
ally contain numerous macrophages that produce matrix
etalloproteinases (MMPs) capable of degradation of ex-
racellular matrix molecules. Plaques with a weakened fi-
rous cap may rupture and provoke thrombosis (11–13). It
as been previously reported that macrovascular and micro-
ascular EC in human plaques also overexpress MMPs (11).
We hypothesized that CRP induces MMP expression in
Cs. Furthermore, we analyzed different mitogen-activated
rotein kinases (MAPK) cascades in regulation of MMPs
xpression. In addition, we examined the levels of candidate
roteins in plasma of subjects in relation to systemic CRP
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CRP Induces Endothelial MMP-1 and -10 April 4, 2006:1369–78evels, and the expression of CRP and MMPs in human
therosclerotic lesions.
Our findings suggest that CRP can increase both endo-
helial and systemic MMP expression, and may thus func-
ion as both marker and mediator of plaque inflammation.
ETHODS
RP stimulation in human ECs. Human umbilical vein
ndothelial cells (HUVECs) were isolated as previously
escribed (14) and grown in MEM 199 (Invitrogen, Carls-
ad, California) supplemented with 10% fetal calf serum
nd 5% human serum (both PAA Laboratories, Pasching,
ustria). Cryopreserved human aortic endothelial cells
HAEC) (Cambrex, East Rutherford, New Jersey) were
btained at passage 3. Human umbilical vein ECs and
AEC (n  4) were incubated for 12 h in presence or
bsence of 50 g/ml human recombinant CRP (Cal-
iochem, San Diego, California), as previously reported
ased on previous observations in endothelial cultures
5,6). C-reactive protein purity was checked by SDS-
AGE followed by Coomasie staining and endotoxin-
ontamination-excluded by polymyxin-B (50 g/ml, Sigma,
t. Louis, Missouri) and Limulus assay (endotoxin 0.125
U/ml, Chromogenix AB, Mölndal, Sweden). To assess a
ossible effect of sodium azide in the commercial prepara-
ion, cells were incubated with 0.025% sodium azide,
quivalent to that found in 50 g/ml CRP. Specific inhib-
tors for MEK (PD98059, 50 M, Sigma, St. Louis,
issouri), p38 (SB203580, 1 M, Sigma), and Jun
-terminal kinase (JNK) (SP600125, 1 M, Calbiochem)
ere added 30 min before CRP incubation. Trypan blue
taining assessed cell viability.
ffymetrix microarray analysis. A total of 10 g of total
ibonucleic acid from HUVEC, isolated with TRIPURE
Roche, Burlington, North Carolina) and purified by
Neasy kit (Qiagen, Hilden, Germany), were used to
enerate and label cRNA according to the manufacturer’s
nstructions. Target quality was ensured by hybridization
Abbreviations and Acronyms
BMI  body mass index
CCA  common carotid arteries
CRP  C-reactive protein
EC  endothelial cell
ERK  extracellular signal-regulated kinase
HAEC  human aortic endothelial cell
HUVEC  human umbilical vein endothelial cell
IMT  intima-media thickness
JNK  Jun N-terminal kinase
MAPK  mitogen-activated protein kinases
MMP  matrix metalloproteinase
RT-PCR  reverse transcription-polymerase chain
reaction
TIMP  tissue inhibitor of metalloproteinase
vWf  von Willebrand factorith a Test3 Array (Affymetrix, Santa Clara, California). sach target was hybridized to the GeneChip Human
enome U133A (Affymetrix). Arrays were washed and
tained with streptavidin-phycoerythrin on Affymetrix Flu-
dic Station and scanned on Affymetrix Genechip Scanner.
nitial analysis was performed using Microarray Suite
MAS5.0, Affymetrix) and subsequent analysis carried out
ith TMev (Stanford University, Stanford, California) (15).
ach probe set on the experimental array was compared to
ts counterpart by the Wilcoxon rank sum test, and the
change p value” calculated indicating increase (I), decrease
D), or no change (NC) in gene expression. The resulting p
alues are “two-tailed” spanning the range from 0 to 1, with
alues associated with an increase near 0 and values associ-
ted with a decrease near 1.
eal-time reverse transcription-polymerase chain reac-
ion (RT-PCR). Genes differentially expressed between
RP-stimulated HUVEC and controls were confirmed by
T-PCR using ABI PRISM 7000 Sequence Detection
ystem (Applied Biosystems, Foster City, California), west-
rn blotting, and enzyme immunoassay (ELISA). Reverse
ranscription was performed by converting 2.5 g of total
ibonucleic acid to complementary deoxyribonucleic acid
sing random priming and MMLV reverse transcriptase
Invitrogen).
Complementary deoxyribonucleic acid (50 ng) was am-
lified with SYBR Green PCR Master Mix (Applied
iosystems) using specific primers for MMP-1 (5=-
CGCCAGATTTGCCAAGAG-3= and 5=-TTGACCCT-
AGAGACCTTGGT-3=) and -actin (5=-AGCCTCGCC-
TTGCCGA-3= and 5=-CTGGTGCCTGGGGCG-3=),
esigned by Primer Express software. Matrix metalloproteinase-
0, MMP-9, and tissue inhibitor of metalloproteinase (TIMP)-1
mplifications were performed with specific Taqman assays-
n-demand (Applied Biosystems). Beta-actin was used to
ormalize messenger ribonucleic acid levels.
lobal MMP activity. A total of 30 M fluorogenic
eptide (MCA-Arg-Pro-Lys-Pro-Val-Glu-Nval-Trp-Arg-
ys-[DNP]-NH2) (R&D Systems, Minneapolis, Minne-
ota) was used to assess global MMP activity. Fluorescence
as kinetically assessed on SpectraMAX GeminiXS (Mo-
ecular Devices, Sunnyvale, California) (320 nm excitation
nd 405 nm emission). EDTA (10 mmol/l) was used to
nhibit calcium-dependent activation of MMPs.
estern blotting. Western blotting evaluated the zymo-
ens of MMP-1 and -10 (52 and 54 kDa, respectively)
nd active forms (42 and 44 kDa, respectively). Condi-
ioned media were separated by SDS-PAGE under
educing conditions and electroblotted onto nitrocellu-
ose membrane. Membranes were probed with murine
nti-MMP-1 (1 g/ml, Oncogene) or anti-MMP-10 (1
g/ml, Lab Vision/Neomarkers, Freemont, California)
ollowed by a peroxidase-linked rabbit anti-mouse IgG
1:2000, Zymed, Camarillo, California). Blots were de-
eloped with chemoluminescence (ECL, Amersham Bio-
cience, Piscataway, New Jersey) on ChemiDoc system
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April 4, 2006:1369–78 CRP Induces Endothelial MMP-1 and -10nd quantified by densitometry (QuantityOne, Bio-Rad,
ercules, California).
tudy population. The study population consisted of 70
pparently healthy subjects (57 men, 50  9 years) present-
ng to the internal medicine department for global risk
ssessment. Subjects lacked clinical atherosclerotic disease
ased on absence of history or physical signs of coronary
isease, stroke or peripheral arterial disease, and normal
lectrocardiogram. Exclusion criteria were severely im-
aired renal function, arteritis, connective tissue diseases,
cute infection, and administration of anti-inflammatory,
ntithrombotic, or hormonal therapy in the previous two
eeks.
Cardiovascular risk factors included arterial hypertension
systolic blood pressure 139 mm Hg, and/or diastolic
lood pressure 89 mm Hg, and/or use of antihypertensive
rugs); dyslipidemia (total cholesterol 200 mg/dl, and/or
igh-density lipoprotein cholesterol 40 mg/dl, and/or
ow-density lipoprotein cholesterol 130 mg/dl, and/or use
f cholesterol lowering drugs), obesity (body mass index
BMI] 30 kg/m2); smoking (1 cigarette a day); and
iabetes (fasting glucose 126 mg/dl and/or use of phar-
acological treatment).
Subjects were grouped according to serum CRP concen-
rations used to denote low and high risk for primary
revention (2).
arotid intima-media thickness (IMT). All subjects un-
erwent ultrasonography (ATL 5000 HDI, Philips, Both-
ll, Washington) of common carotid arteries (CCA) to
ssess the carotid IMT as a surrogate marker of subclinical
therosclerosis (16). Carotid IMT was measured 1 cm proxi-
al to the carotid bulb of each CCA at plaque-free sites and
etermined as the average of near- and far-wall measurements.
ntra- and interobserver coefficients of variation were 5% and
0%, respectively.
The local committee on human research approved the
tudy, performed in accordance with the Declaration of Hel-
inki, and all participants gave written informed consent.
rotein immunolocalization in human atherosclerotic
esions. Specimens from 15 patients undergoing carotid
ndarterectomy (75% stenosis) and 20 mammary arteries
ections as controls were fixed with 4% paraformaldehyde
nd paraffin embedded. Serial sections were analyzed by
mmunohistochemistry as described (13), using antibodies
nti-MMP-1 (2 g/ml, Oncogene, Merck-Biosciences,
ottingham, United Kingdom), anti-MMP-10 (10 g/ml,
eomarkers), anti-CRP (80 g/ml, Sigma), anti-CD68
0.2 g/ml, Dako, Carpinteria, California), and anti-von
illebrand factor (vWf) (3.3 g/ml, Dako).
Samples for confocal microscopy (n 5) were frozen and
ut with a sliding microtome. After incubating with primary
ntibodies (overnight, 4°C), 30-m sections were washed
nd incubated (2 h, room temperature) with 10 g/ml Alexa
luor 568 and 488 anti-IgG antibodies (Molecular Probes,
ugene, Oregon). TO-PRO-3 (1.25 M) was used for
uclear counterstaining and slides mounted in SlowFade
I
cntifade reagent (Molecular Probes) and visualized under
onfocal laser microscope (Zeiss LSM-510 Meta, Carl
eiss, Jena, Germany). The specificity of the signal was
hecked in samples processed without primary antibodies.
aboratory analysis. Fasting serum and plasma samples
ere collected by venipuncture, centrifuged (20 min, 1200 g),
nd stored at 80°C until analysis. Plasma fibrinogen
ctivity was measured by clotting assay (Clauss), high-
ensitive CRP by immunoassay (Immulyte, Diagnostic
roduct Corporation, Los Angeles, California), and vWf by
nzyme immunoassay (Asserachrom, Diagnostica Stago,
snières, France).
Matrix metalloproteinase-1, TIMP-1 (Biotrak, Amersham
iosciences), MMP-10, and interleukin-6 (Quantikine,
&D Systems) levels were assayed in conditioned medium
nd plasma by ELISA. Matrix metalloproteinase assays
ecognize the zymogens and active forms. Inter and intra-
ssay coefficients of variation for all ELISAs were 6%.
Serum total cholesterol, high-density lipoprotein
holesterol, low-density lipoprotein cholesterol, triglyc-
rides, and glucose were measured by standard laboratory
echniques.
tatistical analysis. Differences between controls and
timulated cultures were assessed by Mann-Whitney U test.
ormality was assessed by the Shapiro-Wilk test. Normally
able 1. Transcriptional Profiling of MMP and TIMP Genes
n CRP-Stimulated HUVEC
Gene
Fold Change vs.
Controls
“Change
p Value”
MP-1 2.30 0.000020 I
MP-2 0.93 0.500000 NC
MP-3 0.93 0.500000 NC
MP-7 1.00 0.500000 NC
MP-8 1.07 0.500000 NC
MP-9 1.07 0.500000 NC
MP-10 4.92 0.000020 I
MP-11 0.81 0.725952 NC
MP-12 0.87 0.969033 NC
MP-13 0.44 0.500000 NC
MP-14 (MT1-MMP) 0.47 0.088938 NC
MP-15 (MT2-MMP) 0.81 0.822588 NC
MP-16 (MT3-MMP) 0.41 0.500000 NC
MP-17 (MT4-MMP) 0.38 0.057676 NC
MP-19 1.00 0.500000 NC
MP-20 0.25 0.681091 NC
MP-23A 1.23 0.366593 NC
MP-24 (MT5-MMP) 1.23 0.118009 NC
MP-25 (MT6-MMP) 1.00 0.454766 NC
MP-26 1.52 0.194801 NC
MP-27 1.07 0.274048 NC
MP-28 0.54 0.596188 NC
IMP-1 1.07 0.500000 NC
IMP-2 0.93 0.500000 NC
IMP-3 0.57 0.767451 NC
IMP-4 1.52 0.500000 NC
he values close to 0 indicate increase in transcript expression level, and close to 1
ndicate decrease in transcript expression level.
CRP  C-reactive protein; HUVEC  human umbilical vein endothelial cells;
 increase; MMP  matrix metalloproteinase; MT  membrane type; NC  no
hange; TIMP  tissue inhibitor of metalloproteinase.
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CRP Induces Endothelial MMP-1 and -10 April 4, 2006:1369–78istributed continuous variables in patients were expressed
s mean  SD and non-normally distributed as median
interquartile range). Differences in the baseline character-
stics between study groups were evaluated by the Student
igure 1. C-reactive protein (CRP) increases matrix metalloproteinase (MM
ndothelial cell. Reverse transcription-polymerase chain reaction for MM
erformed in CRP-stimulated human umbilical vein endothelial cells (H
RNA copies) obtained. C-reactive protein-induced MMP-1 and -10 e
resented (mean  SEM, n  4) as percentage from controls set as 100%
igure 2. C-reactive protein (CRP) increases endothelial matrix metallo
anner. (A) Matrix metalloproteinase-1 and -10 dose response after inc
nd -10 secretion in conditioned medium after incubation with CRP (5
ctivity assessed by fluorogenic substrates. (D) Representative Weste
ncreased active form/zymogen ratio of MMP-1 and -10 after CRP (50 g/m
ompared with control. RFU  relative fluorescent unit.test for normally or Mann-Whitney U test for non-
ormally distributed variables, and chi-square statistic for
ategorical variables. Pearson’s correlation test assessed uni-
ariate correlations between MMPs and normally or loga-
1 and MMP-10 messenger ribonucleic acid (mRNA) expression in human
9, -10, and tissue inhibitor of metalloproteinases (TIMP)-1 mRNA was
) (12 h, 50 g/ml) and mRNA normalized values (target gene/-actin
sion in human aortic endothelial cell (HAEC) is also shown. Data are
 0.05 compared with control.
nase (MMP)-1 and -10 protein in a concentration and time-dependent
on with CRP (10 to 100 g/ml) for 12 h. (B) Time course of MMP-1
ml) for 24 h. (C) C-reactive protein-induced (50 g/ml) global MMP
ot of MMP-1 and -10 and densitometric analysis corresponding toP)-
P-1, -
UVEC
xpresprotei
ubati
0 g/
rn bll) stimulation. Data are presented as mean  SEM (n  4). *p  0.05
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April 4, 2006:1369–78 CRP Induces Endothelial MMP-1 and -10ithmically transformed non-normally distributed variables
CRP, triglycerides, glucose, vWf, and carotid IMT). Mul-
ivariable linear regression analysis was conducted with
MP-1 or -10 as dependent variables including in the
odel the traditional risk factors and those variables that
ere significant in the univariate analysis. Statistical signif-
cance was established as p  0.05 (version 11.0, SPSS Inc.,
hicago, Illinois).
ESULTS
ranscriptional profiling. The concentration dependence
f EC activation by CRP (10 to 100 g/ml) was assessed by
easuring interleukin-6 release as described (7). Increased
nterleukin-6 production was observed at 25 g/ml, being
ignificant (p  0.05) at 50 g/ml (two-fold increase in
elation to unstimulated cultures, data not shown), the level
hosen for further analysis.
Microarray analysis of stimulated and control HUVEC
howed at least two-fold increase in the expression of 181
enes while 79 genes decreased by two-fold in CRP-treated
ersus untreated HUVEC (data not shown). We focus on
egulation of genes involved in vascular proteolysis, namely
MPs and TIMPs. C-reactive protein stimulated MMP-1
nd -10 messenger ribonucleic acid expression (2.3- and
.9-fold, respectively; both p  0.001), whereas variations
n TIMPs and other MMPs gene expression showed no
ignificant differences (Table 1).
RP augments MMP-1 and -10 expression in human
C. C-reactive protein increased MMP-1 and -10 expres-
ion in HUVEC, assessed by RT-PCR (2.3  0.6-fold and
.2  1.4-fold change vs. control, respectively, both p 
.014), but did not change MMP-9 or TIMP-1 expression
ignificantly, in accordance with microarray data. C-reactive
rotein also increased significantly MMP-1 and -10 expres-
ion in HAEC (p  0.01) (Fig. 1).
Addition of CRP (10 to 100 g/ml) increased MMP-1
nd -10 secretion in HUVEC-conditioned medium in a
ose-dependent manner (Fig. 2A). The baseline levels of
MP-1 and -10 (17.8  0.7 ng/ml and 15.8  1.0 ng/ml,
espectively) were significantly increased (1.5  0.1-fold
nd 2.8 0.2-fold, respectively, both p 0.001) after CRP
timulation (50 g/ml), whereas TIMP-1 levels did not
hange significantly (data not shown). To exclude any effect
f azide (17,18), 0.025% sodium azide was added to EC
ithout changes on MMP-10 ribonucleic acid expression (1.3
0.1-fold increase as compared with control cultures) or
rotein secretion (10.5  0.3 ng/ml vs. 14.4  1.6 ng/ml in
ontrol cultures), indicating that its presence was irrelevant.
As shown in Figure 2B, CRP induced a time-dependent
ncrease of MMP-1 and -10, starting at 6 h until 24 h (p 
.001). Global MMP activity also assessed in conditioned
edium by a kinetic fluorescence assay was 25% higher in
RP-treated than in control cells (p  0.001) (Fig. 2C).
ddition of EDTA (10 mmol/l) to the medium eliminatedny detectable fluorescence. tInterestingly, significant increases of the proportion of
ctive protein/zymogen of MMP-1 and -10 (1.5  0.5-fold
nd 2.2  0.7-fold change vs. control, respectively; both
 0.014) were observed by western blotting in CRP-
timulated HUVEC compared to controls (Fig. 2D).
Overall, these results suggest that CRP directly induces
ndothelial proteolysis by stimulating expression and activ-
ty of MMP-1 and -10.
ole of MAPK pathways in CRP-mediated MMP-1
nd -10 induction. The specific roles of extracellular
ignal-regulated kinase (ERK)1/2, p38, and Junk in the
egulation of MMP-1 and -10 expression were examined
n HUVEC treated with CRP alone, or in combination
ith MEK1/2 inhibitor PD98059, p38 MAPK-specific
nhibitor SB203580, or JNK inhibitor SP600125. The
nhancement of MMP-1 by CRP was suppressed by
D98059 and SB203580, whereas SP600125 had no
ffect (Fig. 3A). The CRP-induced MMP-10 up-
egulation was blocked by simultaneous inhibition of p38
nd JNK pathways, but not by SB203580 or SP600125
lone (Fig. 3B), suggesting that MAPK signal transduc-
igure 3. Mitogen-activated protein kinase-mediated C-reactive protein
CRP)-induced matrix metalloproteinase (MMP)-1 (A) and MMP-10 (B)
p-regulation. (A) An MEK inhibitor (PD98059) abolished the CRP-
nduced MMP-1 expression, whereas a p38 inhibitor (SB203580) partially
educed it. (B) Both SB203580 and SP600125 (a JNK inhibitor) blocked
he CRP-induced MMP-10 up-regulation. *p  0.05 vs. control; †p 
.05 vs. CRP.ion is involved in MMP induction.
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CRP Induces Endothelial MMP-1 and -10 April 4, 2006:1369–78irculating levels of MMPs and TIMP-1 in relation to
RP. Seventy apparently healthy subjects were stratified
ccording to their serum CRP (Table 2). Subjects with
igh-sensitive CRP levels 3 mg/l had significantly higher
lucose (p 0.04), triglycerides (p 0.03), fibrinogen (p
.001), vWf (p  0.001), BMI (p  0.001), and carotid
MT (p  0.02) than subjects with CRP 3 mg/l. A
ignificant increase of plasma MMP-1 and -10 (p  0.03
nd p  0.02, respectively) was observed in this group,
ithout differences in TIMP-1 levels.
C-reactive protein significantly correlated with MMP-1
nd -10 (r  0.36, p  0.001; r  0.46, p  0.001,
espectively) in the univariate analysis (Table 3). Matrix
etalloproteinase-1 also correlated with BMI (r  0.34,
 0.001) and triglycerides (r  0.32, p  0.001), whereas
MP-10 positively correlated with age (r  0.28, p 
.02), fibrinogen (r 0.36, p 0.001), vWf (r 0.30, p
.02), and TIMP-1 (r  0.47, p  0.001), and inversely
ith high-density lipoprotein cholesterol (r  0.32, p 
.001).
Interestingly, the association between CRP and both
MP-1 (p  0.040) and MMP-10 (p  0.008) remained
ignificant after adjusting for traditional risk factors and
nflammatory markers (Table 4).
Considering wall thickness (values higher or lower than
5th percentile of carotid IMT) as a surrogate of athero-
clerosis, subjects in the highest IMT quartile (0.79 mm)
ad significantly higher plasma MMP-10 levels than those
n the lowest quartile (670.4  181.4 pg/ml vs. 532.2 
56.6 pg/ml, p  0.009).
mmunolocalization of CRP, MMP-1, and -10 in human
rteries. Immunohistochemical staining for CRP, MMP-1,
Table 2. Baseline Characteristics and Biochem
to CRP Levels
CRP
(n
Age, yrs 48.4
Gender, M/F 2
Body mass index, kg/m2 26.1
Glucose, mg/dl* 92 (8
Total cholesterol, mg/dl 220.6
HDL-C, mg/dl 51.3
LDL-C, mg/dl 148.2
Triglycerides, mg/dl* 85 (5
Smoking, N/Y 2
Systolic blood pressure, mm Hg* 120 (1
Diastolic blood pressure, mm Hg* 80 (7
CRP, mg/l* 1 (0
Fibrinogen, mg/dl 282.4
von Willebrand factor, %* 91 (7
MMP-1, ng/ml 4.0
MMP-10, pg/ml 558.0
TIMP-1, ng/ml 92.8
Carotid IMT, mm* 0.67 (0
Values are expressed as mean  SD, except for skewed vari
HDL-C  high-density lipoprotein-cholesterol; IMT 
abbreviations as in Table 1.nd MMP-10 was performed in vascular sections from carotid
*nd mammary artery specimens (Fig. 4). An intense positive
ignal for these proteins was observed in all carotid sections
nalyzed (Figs. 4A to 4C), whereas a weaker signal was found
n mammary arteries (Figs. 4G to 4I). The strongest immu-
ostaining corresponds to macrophage-rich areas within end-
rterectomy specimens (Fig. 4D). Interestingly, a positive
ignal for both MMP-10 and CRP was observed within the
ndothelial layer (Figs. 4E and 4F). Confocal microscopy
onfirmed the colocalization of MMP-10 and CRP in
acrophage-rich areas and in the endothelial layer (Fig. 5).
rofile of Subjects Stratified According
g/l
)
CRP >3 mg/l
(n  37) p Value
51.8  9.4 0.12
30/7 0.94
29.0  3.3 0.001
) 99 (92–110) 0.04
.3 239.0  38.7 0.06
.0 49.8  14.7 0.62
.8 164.1  37.0 0.09
) 112 (84–153) 0.03
23/14 0.89
0) 135 (113–150) 0.67
80 (80–90) 0.95
.25) 6 (5.10–8.75) 0.001
.2 337.1  78.3 0.001
) 123 (90–160) 0.001
4.6  1.1 0.03
.8 737.8  71.2 0.02
.0 101.9  17.3 0.06
.74) 0.70 (0.65–0.85) 0.02
which are shown as median (interquartile range).
-media thickness; LDL-C  low-density lipoprotein; other
able 3. Correlation Coefficients Between MMP-1, MMP-10,
nd Cardiovascular Risk Factors
MMP-1 MMP-10
(r) p (r) p
ge, yrs 0.092 0.49 0.28 0.02
MI, kg/m2 0.34 0.001 0.16 0.17
lucose, mg/dl* 0.22 0.09 0.16 0.19
otal cholesterol, mg/dl 0.11 0.41 0.06 0.63
DL-C, mg/dl 0.054 0.709 0.32 0.001
DL-C, mg/dl 0.13 0.33 0.03 0.80
riglycerides, mg/dl* 0.32 0.001 0.07 0.58
ystolic blood pressure,
mm Hg
0.23 0.08 0.19 0.12
iastolic blood pressure,
mm Hg
0.09 0.5 0.17 0.15
RP, mg/l* 0.36 0.001 0.46 0.001
ibrinogen, mg/dl 0.20 0.13 0.36 0.001
on Willebrand factor, %* 0.22 0.10 0.30 0.02
MP-1, ng/ml — — 0.08 0.569
IMP-1, ng/ml 0.23 0.12 0.47 0.001
arotid IMT, mm* 0.06 0.71 0.24 0.053ical P
<3 m
 33
 8.9
7/6
 3.4
8–103
 43
 12
 41
5–116
1/12
10–13
8–85)
.95–1
 66
0–119
 0.5
 30
 13
.60–0
ables*,Skewed variables that were logarithmically transformed.
BMI  body mass index; other abbreviations as in Tables 1 and 2.
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April 4, 2006:1369–78 CRP Induces Endothelial MMP-1 and -10ISCUSSION
atrix metalloproteinases may contribute to the develop-
ent of unstable plaques. This study demonstrates that
RP induces endothelial MMP-1 and -10 expression, and
levated CRP levels are associated with increased MMP-1
nd -10 expression in vivo, providing a link between inflam-
ation and atherosclerotic plaque destabilization.
xpression of MMPs by ECs in response to CRP. De-
pite reports showing proatherogenic properties of CRP on
C (5–8,19), there is scarce evidence of its role on vascular
roteolytic potential (20). A novel finding was that CRP
ignificantly increased messenger ribonucleic acid and pro-
ein expression of MMP-1 and -10 in HUVEC and
AEC, without significantly affecting the expression of
ther MMPs or TIMPs, as assessed by transcriptional
rofiling and verified by RT-PCR and immunological
ethods. A previous analysis demonstrated increased ex-
ression of both MMPs by EC upon stimulation with
xidized high-density lipoprotein (21).
C-reactive protein also increased global MMP activity
nd the proportion active protein/zymogen of MMP-1 and
10, suggesting increased endothelial proteolytic activation,
ot explained by increased chymase/tryptase, urokinase-type
lasminogen activator, or thrombin, because their transcrip-
ional profile was not altered (data not shown). Matrix
etalloproteinase-1 and MMP-10, by degrading major
xtracellular matrix components in atherosclerotic plaques
12), might promote superficial erosion of the intima, an
mportant process leading to coronary thrombosis (22,23).
The mechanisms of CRP-mediated stimulation of
MP-1 and -10 in HUVEC are not fully characterized.
-reactive protein stimulates MMP-1 and annexin A5
xpression by U937 cells via Fc receptors and ERK
athway (20,24). It has also been suggested that conforma-
ional rearrangement of CRP via FcRIII (CD16) may be a
rerequisite for activation of EC independently of CD32
25). In contrast to mature EC, HUVEC do not express
D32 nor CD16 receptors, therefore suggesting an Fc
able 4. Correlation of CRP With MMP-1 and -10
n Multiple Linear Regression Analysis With MMP-1 and
10 as Dependent Variables
B SE(B) p Partial R2 (%)
MP-1*
CRP, mg/l 3.11 1.6 0.040 30.0
BMI, kg/m2 0.098 0.039 0.017 34.8
MP-10†
CRP, mg/l 12.49 4.568 0.008 34.6
Gender 193.56 93.30 0.043 26.9
Smoking 197.23 70.71 0.007 35.2
Fibrinogen, mg/dl 1.43 0.479 0.004 37.4
R2  19.8% for the total population (p  0.015) (adjusted for age, gender, smoking,
ody mass index (BMI), glucose, total cholesterol, systolic blood pressure, triglycer-
des, and CRP); †R2  47.6% for the total population (p  0.001) (adjusted for age,
ender, smoking, BMI, glucose, total cholesterol, systolic blood pressure, HDL-C,
RP, fibrinogen, von Willebrand factor, TIMP-1, and carotid IMT).
Abbreviations as in Tables 1 and 2.eceptor-independent induction of proteinase expression. aIn this study, we also demonstrated that the MAPK
ignaling cascade constitutes one of the possible pathways
hat mediates the effect of CRP on endothelial MMP
roduction; ERK1/2, p38, and JNK pathways have been
eported to be involved in the regulation of MMP-1 and -10
n different cell types (20,26,27), and there is evidence that
RP could activate the MEK/ERK signaling pathway in
UVEC (28).
In addition, CRP can contribute to the extent of vascular
amage via complement activation (29). Atherogenic fac-
ors, such as cytokines and oxidized low-density lipoprotein,
nown to increase CRP, may also stimulate MMP-1
ctivity by cells present within atheroma (30,31).
ystemic levels of MMP-1 and -10 in relation to serum
RP. Significant associations of CRP with MMP-1 and
9 have been found in patients with cardiovascular disease
32) and rheumatoid arthritis (33). To further explore in
itro findings, systemic levels of MMP-1 and -10 were
easured in asymptomatic subjects stratified according to
RP values. Patients at high cardiovascular risk (2) (CRP
3 mg/l) showed higher plasma MMP-1 and -10 and
ncreased carotid IMT, a surrogate marker of atherosclerosis
34). The association between CRP and both MMPs
emained significant after adjusting for cardiovascular risk
actors. These observations suggest a close relationship
etween ongoing inflammatory markers and systemic pro-
eolytic activation with subclinical atherosclerosis, and ex-
end previous data showing that elevated CRP also predicts
ecurrent instability and mortality in patients with coronary
isease (35,36).
mmunohistochemistry for CRP, MMP-1, and -10 in
uman arteries. C-reactive protein can accumulate in ath-
rosclerotic lesions and may be expressed by cells in ad-
anced atherosclerotic plaques (37,38). In addition, eleva-
ion of both MMP-1 and -10 has been reported in these
laques (11,12,39).
Our present novel observations demonstrate increased
RP, MMP-1, and MMP-10 in macrophage-rich regions
rom endarterectomy specimens as compared with mam-
ary arteries. C-reactive protein and MMP-10 also showed
strong signal within the endothelial layer of advanced
uman atherosclerotic plaques. This novel finding could be
elated to the presence of CRP adsorbed and transported
nto the arterial wall as previously described (5,25), also in
greement with a recent in vitro study showing CRP
xpression in HAEC (40).
Interestingly, CRP and MMP-10 colocalized within
egions previously described as rupture prone. Given the
mportance of MMPs in weakening atherosclerotic plaques
22,30,41), increased local and systemic MMP activation
ay contribute to the association of CRP with cardiovas-
ular events caused by plaque complication.
tudy limitations. This study did not assess the effect of
RP on collagen synthesis; however, previous studies
howed no increase in collagen synthesis in advanced
therosclerotic lesions (13). Our in vivo and in vitro data are
c
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lthough a cause/effect relationship cannot be assumed. The
RP concentrations employed in vitro were higher than
igure 4. (A to C) Representative immunohistochemical analysis of C-rea
ections of human atherosclerotic plaques. Area squared in red correspond
RP, MMP-1, and MMP-10 within macrophage-rich areas (CD-68
ndothelial cell, positive for von Willebrand factor (vWf), also expressed
MP-10 in control mammary arteries.hose observed in the plasma of patients at high cardiovas- rular risk. However, because the CRP mRNA levels in
therosclerotic plaques are 10-fold higher than in normal
rteries (42), it is likely that local CRP levels in atheroscle-
protein (CRP), matrix metalloproteinases (MMP)-1, and -10 in adjacent
agnified details. Higher magnification revealed intense positive signal for
e) (D). Magnification detail of endothelial layer (100) showed that
P-10 (E and F). (G to I) Inmmunolocalization of CRP, MMP-1, andctive
s to m
positiv
MMotic lesion are sufficient to stimulate MMP secretion by
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April 4, 2006:1369–78 CRP Induces Endothelial MMP-1 and -10C. Finally, another report found no effect of CRP on
UVEC, likely due to different experimental conditions
different culture medium and supplement growth factors)
20).
The present study adds to evidence that CRP may not
erely serve as a marker but also as a proatherogenic factor
nd regulator of plaque biology through endothelial prote-
lysis, thus providing a link between inflammation and
laque instability.
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